Long-term treatment with Nucala (mepolizumab) — approved for use in EGPA, or eosinophilic granulomatosis with polyangiitis, the rarest type…
Articles by Margarida Maia, PhD
A Phase 1 clinical trial assessing SC291, an experimental CAR T-cell therapy that Sana Biotechnology is developing for…
A graphic prediction tool may accurately estimate the chance of survival over two years in people ANCA-associated vasculitis (AAV),…
Physicians typically do not overestimate the overall health of people with ANCA-associated vasculitis (AAV), a study of global assessments…
Adicet Bio has pushed to the second half of 2025 the expected timing for enrolling patients with ANCA-associated…
More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses,…
Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy…
Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults…
People with ANCA-associated vasculitis (AAV) who carry certain variants in SERPINA1 — a gene that’s been previously linked to…
Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of…